{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T22:59:50Z","timestamp":1790895590981,"version":"4.1.0"},"reference-count":49,"publisher":"American Society of Hematology","issue":"15","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,8,12]]},"abstract":"<jats:sec>\n                  <jats:title>Abstract<\/jats:title>\n                  <jats:p>Paroxysmal nocturnal hemoglobinuria (PNH) and primary complement\u2013mediated thrombotic microangiopathy, also known as atypical hemolytic uremic syndrome (aHUS), are hematologic disorders characterized by dysregulation of the complement system leading to hemolysis and other systemic and potentially lethal complications. The advent of C5 inhibition with agents such as eculizumab and ravulizumab has revolutionized the management of patients with these disorders, although some may still experience clinically significant breakthrough extravascular hemolysis. Over the past several years, novel therapies targeting upstream pathways of complement inhibition have been approved for the treatment of patients with PNH experiencing breakthrough hemolysis despite C5 inhibition. These agents currently include pegcetacoplan, a C3 inhibitor; iptacopan, an oral factor B inhibitor; danicopan, an oral factor D inhibitor; and crovalimab, an anti-C5 monoclonal antibody. This review highlights recent advances in complement-targeted therapies for PNH, including their indications and efficacy and safety data from key randomized trials. In addition, we review current data supporting the use of these novel agents for aHUS, for which only the terminal complement inhibitors eculizumab and ravulizumab are currently approved. Future research is crucial to establish the long-term efficacy and safety profiles of these novel therapies, ensuring the best treatment strategies for patients with PNH and aHUS.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1182\/bloodadvances.2024015777","type":"journal-article","created":{"date-parts":[[2025,5,12]],"date-time":"2025-05-12T13:22:29Z","timestamp":1747056149000},"page":"3937-3945","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":14,"title":["Advancements in complement inhibition for PNH and primary complement\u2013mediated thrombotic microangiopathy"],"prefix":"10.1182","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0009-0002-8164-8177","authenticated-orcid":false,"given":"Thalia","family":"Padilla Kelley","sequence":"first","affiliation":[{"name":"1Department of Medicine, Oregon Health & Science University, Portland, OR"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3762-010X","authenticated-orcid":false,"given":"Hannah","family":"King","sequence":"additional","affiliation":[{"name":"1Department of Medicine, Oregon Health & Science University, Portland, OR"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aditya","family":"Malhotra","sequence":"additional","affiliation":[{"name":"2Division of Hematology and Medical Oncology, Oregon Health & Science University, Portland, OR"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas G.","family":"DeLoughery","sequence":"additional","affiliation":[{"name":"2Division of Hematology and Medical Oncology, Oregon Health & Science University, Portland, OR"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kylee","family":"Martens","sequence":"additional","affiliation":[{"name":"2Division of Hematology and Medical Oncology, Oregon Health & Science University, Portland, OR"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph J.","family":"Shatzel","sequence":"additional","affiliation":[{"name":"2Division of Hematology and Medical Oncology, Oregon Health & Science University, Portland, OR"},{"name":"3Department of Biomedical Engineering, Oregon Health & Science University, Portland, OR"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2025,7,30]]},"reference":[{"issue":"1","key":"2025081209513392800_bib1","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1002\/j.1460-2075.1994.tb06240.x","article-title":"Paroxysmal nocturnal haemoglobinuria (PNH) is caused by somatic mutations in the PIG-A gene","volume":"13","author":"Bessler","year":"1994","journal-title":"EMBO J"},{"issue":"7","key":"2025081209513392800_bib2","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1007\/s00277-023-05269-4","article-title":"Relationship of paroxysmal nocturnal hemoglobinuria (PNH) granulocyte clone size to disease burden and risk of major vascular events in untreated patients: results from the International PNH Registry","volume":"102","author":"Dingli","year":"2023","journal-title":"Ann Hematol"},{"issue":"12","key":"2025081209513392800_bib3","doi-asserted-by":"crossref","first-page":"3699","DOI":"10.1182\/blood-2005-04-1717","article-title":"Diagnosis and management of paroxysmal nocturnal hemoglobinuria","volume":"106","author":"Parker","year":"2005","journal-title":"Blood"},{"issue":"6","key":"2025081209513392800_bib4","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1182\/blood-2018-09-876136","article-title":"Ravulizumab (ALXN1210) vs eculizumab in adult patients with PNH naive to complement inhibitors: the 301 study","volume":"133","author":"Lee","year":"2019","journal-title":"Blood"},{"issue":"24","key":"2025081209513392800_bib5","doi-asserted-by":"crossref","first-page":"2528","DOI":"10.1182\/blood.2024025850","article-title":"Complement biosensors identify a classical pathway stimulus in complement-mediated thrombotic microangiopathy","volume":"144","author":"Cole","year":"2024","journal-title":"Blood"},{"issue":"6","key":"2025081209513392800_bib6","doi-asserted-by":"crossref","first-page":"I34","DOI":"10.1016\/j.vaccine.2008.11.059","article-title":"Mechanisms in Neisseria meningitidis for resistance against complement-mediated killing","volume":"2 Suppl 8","author":"Kugelberg","year":"2008","journal-title":"Vaccine"},{"issue":"11","key":"2025081209513392800_bib7","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1056\/NEJMoa2029073","article-title":"Pegcetacoplan versus eculizumab in paroxysmal nocturnal hemoglobinuria","volume":"384","author":"Hillmen","year":"2021","journal-title":"N Engl J Med"},{"issue":"11","key":"2025081209513392800_bib8","doi-asserted-by":"crossref","first-page":"1334","DOI":"10.1002\/ajh.25960","article-title":"C3 inhibition with pegcetacoplan in subjects with paroxysmal nocturnal hemoglobinuria treated with eculizumab","volume":"95","author":"de Castro","year":"2020","journal-title":"Am J Hematol"},{"issue":"8","key":"2025081209513392800_bib9","doi-asserted-by":"crossref","first-page":"3099","DOI":"10.1182\/blood-2008-01-133918","article-title":"Paroxysmal nocturnal hemoglobinuria: natural history of disease subcategories","volume":"112","author":"de Latour","year":"2008","journal-title":"Blood"},{"issue":"suppl 4","key":"2025081209513392800_bib10","first-page":"S44","article-title":"Complement-driven hemolytic uremic syndrome","volume":"98","author":"Leon","year":"2023","journal-title":"Am J Hematol"},{"issue":"2","key":"2025081209513392800_bib11","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1111\/bjh.15790","article-title":"Eculizumab in paroxysmal nocturnal haemoglobinuria and atypical haemolytic uraemic syndrome: 10-year pharmacovigilance analysis","volume":"185","author":"Soci\u00e9","year":"2019","journal-title":"Br J Haematol"},{"issue":"12","key":"2025081209513392800_bib12","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1056\/NEJMoa061648","article-title":"The complement inhibitor eculizumab in paroxysmal nocturnal hemoglobinuria","volume":"355","author":"Hillmen","year":"2006","journal-title":"N Engl J Med"},{"issue":"suppl 12-B","key":"2025081209513392800_bib28","first-page":"S14","article-title":"Paroxysmal nocturnal hemoglobinuria: current treatments and unmet needs","volume":"26","author":"Bektas","year":"2020","journal-title":"J Manag Care Spec Pharm"},{"key":"2025081209513392800_bib29","first-page":"6093695","article-title":"A case of fulminant meningococcemia: it is all in the complement","volume":"2017","author":"Hawkins","year":"2017","journal-title":"Case Rep Infect Dis"},{"issue":"1","key":"2025081209513392800_bib26","doi-asserted-by":"crossref","first-page":"230","DOI":"10.3324\/haematol.2019.236877","article-title":"Characterization of breakthrough hemolysis events observed in the phase 3 randomized studies of ravulizumab versus eculizumab in adults with paroxysmal nocturnal hemoglobinuria","volume":"106","author":"Brodsky","year":"2021","journal-title":"Haematologica"},{"issue":"11","key":"2025081209513392800_bib30","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1056\/NEJMoa1502950","article-title":"Eculizumab in pregnant patients with paroxysmal nocturnal hemoglobinuria","volume":"373","author":"Kelly","year":"2015","journal-title":"N Engl J Med"},{"issue":"5","key":"2025081209513392800_bib13","doi-asserted-by":"crossref","first-page":"e344","DOI":"10.1016\/S2352-3026(21)00028-4","article-title":"Addition of iptacopan, an oral factor B inhibitor, to eculizumab in patients with paroxysmal nocturnal haemoglobinuria and active haemolysis: an open-label, single-arm, phase 2, proof-of-concept trial","volume":"8","author":"Risitano","year":"2021","journal-title":"Lancet Haematol"},{"issue":"16","key":"2025081209513392800_bib14","doi-asserted-by":"crossref","first-page":"7926","DOI":"10.1073\/pnas.1820892116","article-title":"Small-molecule factor B inhibitor for the treatment of complement-mediated diseases","volume":"116","author":"Schubart","year":"2019","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"15","key":"2025081209513392800_bib15","doi-asserted-by":"crossref","first-page":"4450","DOI":"10.1182\/bloodadvances.2022006960","article-title":"Iptacopan monotherapy in patients with paroxysmal nocturnal hemoglobinuria: a 2-cohort open-label proof-of-concept study","volume":"6","author":"Jang","year":"2022","journal-title":"Blood Adv"},{"issue":"7","key":"2025081209513392800_bib16","doi-asserted-by":"crossref","first-page":"1332","DOI":"10.1016\/j.ekir.2023.04.029","article-title":"Design and rationale of the APPELHUS phase 3 open-label study of factor B inhibitor iptacopan for atypical hemolytic uremic syndrome","volume":"8","author":"Kavanagh","year":"2023","journal-title":"Kidney Int Rep"},{"issue":"suppl 1","key":"2025081209513392800_bib17","doi-asserted-by":"crossref","first-page":"2175","DOI":"10.1182\/blood-2021-148042","article-title":"Evaluation of the long-term safety and efficacy of pegcetacoplan treatment for paroxysmal nocturnal hemoglobinuria patients: an extension study","volume":"138","author":"Hoffman","year":"2021","journal-title":"Blood"},{"issue":"7","key":"2025081209513392800_bib18","doi-asserted-by":"crossref","first-page":"1776","DOI":"10.1182\/bloodadvances.2023011691","article-title":"Management of acute breakthrough hemolysis with intensive pegcetacoplan dosing in patients with PNH","volume":"8","author":"Griffin","year":"2024","journal-title":"Blood Adv"},{"key":"2025081209513392800_bib19","doi-asserted-by":"crossref","first-page":"20406207221114673","DOI":"10.1177\/20406207221114673","article-title":"Safety and efficacy of pegcetacoplan in paroxysmal nocturnal hemoglobinuria","volume":"13","author":"Wong","year":"2022","journal-title":"Ther Adv Hematol"},{"issue":"11","key":"2025081209513392800_bib20","doi-asserted-by":"crossref","first-page":"2468","DOI":"10.1182\/bloodadvances.2022009129","article-title":"Pegcetacoplan controls hemolysis in complement inhibitor-naive patients with paroxysmal nocturnal hemoglobinuria","volume":"7","author":"Wong","year":"2023","journal-title":"Blood Adv"},{"issue":"20","key":"2025081209513392800_bib21","doi-asserted-by":"crossref","first-page":"1928","DOI":"10.1182\/blood.2021011388","article-title":"Phase 2 study of danicopan in patients with paroxysmal nocturnal hemoglobinuria with an inadequate response to eculizumab","volume":"138","author":"Kulasekararaj","year":"2021","journal-title":"Blood"},{"issue":"12","key":"2025081209513392800_bib22","doi-asserted-by":"crossref","first-page":"3188","DOI":"10.3324\/haematol.2020.261826","article-title":"Danicopan: an oral complement factor D inhibitor for paroxysmal nocturnal hemoglobinuria","volume":"106","author":"Risitano","year":"2021","journal-title":"Haematologica"},{"issue":"9","key":"2025081209513392800_bib23","doi-asserted-by":"crossref","first-page":"1768","DOI":"10.1002\/ajh.27412","article-title":"Phase 3 randomized COMMODORE 2 trial: crovalimab versus eculizumab in patients with paroxysmal nocturnal hemoglobinuria naive to complement inhibition","volume":"99","author":"R\u00f6th","year":"2024","journal-title":"Am J Hematol"},{"issue":"S3","key":"2025081209513392800_bib24","doi-asserted-by":"crossref","first-page":"e72750f1","DOI":"10.1097\/01.HS9.0000967636.72750.f1","article-title":"S181: The phase III, randomized commodore 2 trial: results from a multicenter study of crovalimab vs eculizumab in paroxysmal nocturnal hemoglobinuria (PNH) patients naive to complement inhibitors [abstract]","volume":"7","author":"R\u00f6th","year":"2023","journal-title":"HemaSphere"},{"issue":"2","key":"2025081209513392800_bib25","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1111\/ejh.14011","article-title":"Crovalimab treatment in patients with paroxysmal nocturnal haemoglobinuria: long-term results from the phase I\/II COMPOSER trial","volume":"111","author":"R\u00f6th","year":"2023","journal-title":"Eur J Haematol"},{"issue":"3","key":"2025081209513392800_bib27","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1111\/ejh.13564","article-title":"One-year outcomes from a phase 3 randomized trial of ravulizumab in adults with paroxysmal nocturnal hemoglobinuria who received prior eculizumab","volume":"106","author":"Kulasekararaj","year":"2021","journal-title":"Eur J Haematol"},{"issue":"6","key":"2025081209513392800_bib31","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1182\/blood-2018-09-876805","article-title":"Ravulizumab (ALXN1210) vs eculizumab in C5-inhibitor-experienced adult patients with PNH: the 302 study","volume":"133","author":"Kulasekararaj","year":"2019","journal-title":"Blood"},{"issue":"1","key":"2025081209513392800_bib32","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1053\/j.ajkd.2015.12.034","article-title":"Terminal complement inhibitor eculizumab in adult patients with atypical hemolytic uremic syndrome: a single-arm, open-label trial","volume":"68","author":"Fakhouri","year":"2016","journal-title":"Am J Kidney Dis"},{"issue":"5","key":"2025081209513392800_bib33","doi-asserted-by":"crossref","first-page":"261","DOI":"10.5414\/CN110516","article-title":"Comparative efficacy of ravulizumab and eculizumab in the treatment of atypical hemolytic uremic syndrome: an indirect comparison using clinical trial data","volume":"97","author":"Tomazos","year":"2022","journal-title":"Clin Nephrol"},{"issue":"12","key":"2025081209513392800_bib34","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1182\/blood.2019003399","article-title":"The complement C5 inhibitor crovalimab in paroxysmal nocturnal hemoglobinuria","volume":"135","author":"R\u00f6th","year":"2020","journal-title":"Blood"},{"issue":"9","key":"2025081209513392800_bib35","doi-asserted-by":"crossref","first-page":"1757","DOI":"10.1002\/ajh.27413","article-title":"Phase 3 randomized COMMODORE 1 trial: crovalimab versus eculizumab in complement inhibitor-experienced patients with paroxysmal nocturnal hemoglobinuria","volume":"99","author":"Scheinberg","year":"2024","journal-title":"Am J Hematol"},{"issue":"9","key":"2025081209513392800_bib36","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1002\/ajh.26998","article-title":"Efficacy and safety of the C5 inhibitor crovalimab in complement inhibitor-naive patients with PNH (COMMODORE 3): a multicenter, phase 3, single-arm study","volume":"98","author":"Liu","year":"2023","journal-title":"Am J Hematol"},{"issue":"16","key":"2025081209513392800_bib38","doi-asserted-by":"crossref","first-page":"8698","DOI":"10.3390\/ijms25168698","article-title":"Three years on: the role of pegcetacoplan in paroxysmal nocturnal hemoglobinuria (PNH) since its initial approval","volume":"25","author":"Horneff","year":"2024","journal-title":"Int J Mol Sci"},{"issue":"2","key":"2025081209513392800_bib39","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1056\/NEJMra2201664","article-title":"Breakthrough hemolysis in PNH with proximal or terminal complement inhibition","volume":"387","author":"Notaro","year":"2022","journal-title":"N Engl J Med"},{"issue":"5","key":"2025081209513392800_bib40","doi-asserted-by":"crossref","first-page":"2050","DOI":"10.1007\/s12325-024-02827-8","article-title":"Safety and efficacy of pegcetacoplan in adult patients with paroxysmal nocturnal hemoglobinuria over 48 weeks: 307 open-label extension study","volume":"41","author":"Patriquin","year":"2024","journal-title":"Adv Ther"},{"issue":"11","key":"2025081209513392800_bib41","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1056\/NEJMoa2308695","article-title":"Oral iptacopan monotherapy in paroxysmal nocturnal hemoglobinuria","volume":"390","author":"Peffault de Latour","year":"2024","journal-title":"N Engl J Med"},{"issue":"12","key":"2025081209513392800_bib42","doi-asserted-by":"crossref","first-page":"e955","DOI":"10.1016\/S2352-3026(23)00315-0","article-title":"Addition of danicopan to ravulizumab or eculizumab in patients with paroxysmal nocturnal haemoglobinuria and clinically significant extravascular haemolysis (ALPHA): a double-blind, randomised, phase 3 trial","volume":"10","author":"Lee","year":"2023","journal-title":"Lancet Haematol"},{"issue":"22","key":"2025081209513392800_bib43","doi-asserted-by":"crossref","first-page":"2447","DOI":"10.1200\/JCO.21.02389","article-title":"Narsoplimab, a mannan-binding lectin-associated serine protease-2 inhibitor, for the treatment of adult hematopoietic stem-cell transplantation-associated thrombotic microangiopathy","volume":"40","author":"Khaled","year":"2022","journal-title":"J Clin Oncol"},{"issue":"7","key":"2025081209513392800_bib44","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1056\/NEJMoa1311084","article-title":"Genetic variants in C5 and poor response to eculizumab","volume":"370","author":"Nishimura","year":"2014","journal-title":"N Engl J Med"},{"issue":"S3","key":"2025081209513392800_bib45","doi-asserted-by":"crossref","first-page":"e1287903","DOI":"10.1097\/01.HS9.0000970044.12879.03","article-title":"Six-month crovalimab extension in the phase 3 Commodore 3 study: updated efficacy and safety results in complement inhibitor-naive patients (PTS) with paroxysmal nocturnal hemoglobinuria (PNH) [abstract]","volume":"7","author":"Liu","year":"2023","journal-title":"HemaSphere"},{"issue":"12","key":"2025081209513392800_bib46","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1080\/13696998.2020.1831519","article-title":"A US cost-minimization model comparing ravulizumab versus eculizumab for the treatment of atypical hemolytic uremic syndrome","volume":"23","author":"Wang","year":"2020","journal-title":"J Med Econ"},{"key":"2025081209513392800_bib47","article-title":"Indication: As an Add-on to Ravulizumab or Eculizumab for the Treatment of Adult Patients With Paroxysmal Nocturnal Hemoglobinuria Who Have Residual Hemolytic Anemia Due to Extravascular Hemolysis","author":"Danicopan (Voydeya)","year":"2024","journal-title":"Canadian Agency for Drugs and Technologies in Health"},{"key":"2025081209513392800_bib48","article-title":"CADTH Reimbursement Recommendation: Indication: For the Treatment of Adult Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) Who Have an Inadequate Response to, or Are Intolerant of, a C5 Inhibitor","author":"Pegcetacoplan (Empaveli)","year":"2023","journal-title":"Canadian Agency for Drugs and Technologies in Health"},{"issue":"1","key":"2025081209513392800_bib49","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1182\/blood.2024025176","article-title":"Cost-effectiveness of iptacopan for paroxysmal nocturnal hemoglobinuria","volume":"145","author":"Ito","year":"2025","journal-title":"Blood"},{"key":"2025081209513392800_bib50","unstructured":"Prime Therapeutics\n          . Drug approvals: July 2024. Published 31 July 2024. Accessed 30 May 2025. https:\/\/www.primetherapeutics.com\/drug-approvals-july-2024."}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/9\/15\/3937\/2404824\/blooda_adv-2024-015777-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/9\/15\/3937\/2404824\/blooda_adv-2024-015777-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,12]],"date-time":"2025-08-12T13:51:44Z","timestamp":1755006704000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/9\/15\/3937\/537232\/Advancements-in-complement-inhibition-for-PNH-and"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,30]]},"references-count":49,"journal-issue":{"issue":"15","published-print":{"date-parts":[[2025,8,12]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2024015777","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,8,12]]},"published":{"date-parts":[[2025,7,30]]}}}